Glenmark's Ryaltris nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age | News Headlines, Latest News , Business and Political
Efficacy and safety of twice-daily olopatadine–mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis | SpringerLink
Ryaltris olopatadine hydrochloride 665 mcg / mometasone furoate 25 mcg per 0.1 mL nasal spray Images - Pill Identifier